<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276054</url>
  </required_header>
  <id_info>
    <org_study_id>1B-09-12</org_study_id>
    <secondary_id>NCI-2010-02323</secondary_id>
    <nct_id>NCT01276054</nct_id>
  </id_info>
  <brief_title>Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.</brief_title>
  <official_title>Reducing the Incidence and Severity of Arm Lymphedema With Axillary Reverse Mapping and Implementation of a Lymphedema Screening and Intervention Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lymph node biopsy followed by axillary reverse mapping may reduce the incidence and severity
      of arm lymphedema. This randomized phase II trial is studying how well sentinel and/or
      axillary lymph node biopsy with or without axillary reverse mapping works in reducing
      incidence and severity of lymphedema in patients with resectable stage 0-II breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To evaluate the ability of axillary reverse mapping (ARM) to reduce
      the incidence of lymphedema (LE) following axillary nodal staging. SECONDARY OBJECTIVES: I.
      To document the use of a standardized LE screening and LE level-specific management protocol
      on the outcome of LE among patients who develop LE. II. To document the relationship between
      limb volume measurements assessed by infrared laser perometry and bioelectrical impedance
      spectroscopy. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients
      undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using
      technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution
      tracer for localization of the arm lymph node. Patients then undergo and axillary reverse
      mapping. ARM II: Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid
      followed by methylene blue or indocyanine green solution tracer for localization of the arm
      lymph node. After completion of study treatment, patients are followed up at 1-2 weeks, 3
      months, and then every 6 months for 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    P.I. left
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whether or Not a Patient Has Developed Grade 1+ LE</measure>
    <time_frame>During the first year post-operatively</time_frame>
    <description>LE is defined using the CTCAE v3 definition: a &gt;5-10% increase in the inter-limb volume in the ipsilateral arm compared to the unaffected arm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Lymphedema</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IA Breast Cancer</condition>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SNB or ALND (+/- SNB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>technetium Tc 99m sulfur colloid</intervention_name>
    <description>Given intradermally and periareolarly</description>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
    <arm_group_label>SNB or ALND (+/- SNB)</arm_group_label>
    <other_name>Tc 99m Sulfur Colloid</other_name>
    <other_name>Tc-99m SC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylene blue</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
    <arm_group_label>SNB or ALND (+/- SNB)</arm_group_label>
    <other_name>Azul de Metileno</other_name>
    <other_name>Azul Metile</other_name>
    <other_name>Blu di Metilene</other_name>
    <other_name>MB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green solution</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
    <arm_group_label>SNB or ALND (+/- SNB)</arm_group_label>
    <other_name>IC-GREEN</other_name>
    <other_name>ICG solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
    <description>Undergo sentinel lymph node biopsy</description>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
    <arm_group_label>SNB or ALND (+/- SNB)</arm_group_label>
    <other_name>sentinel node biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>axillary lymph node biopsy</intervention_name>
    <description>Undergo axillary lymph node biopsy</description>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
    <arm_group_label>SNB or ALND (+/- SNB)</arm_group_label>
    <other_name>axillary node biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bioimpedance spectroscopy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
    <arm_group_label>SNB or ALND (+/- SNB)</arm_group_label>
    <other_name>BIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
    <arm_group_label>SNB or ALND (+/- SNB)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lymphedema management</intervention_name>
    <description>Undergo axillary reverse mapping</description>
    <arm_group_label>SNB plus ARM or ALND (+/- SNB) plus ARM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 0, I, and II Breast Cancer

          -  Not pregnant or breastfeeding

          -  Breast cancer or prophylactic mastectomy requiring axillary nodal staging

          -  Ability to read and/or comprehend consent form and questionnaires

          -  Ability to follow-up per protocol

          -  Unilateral axillary staging

        Exclusion Criteria:

          -  Stage 3

          -  Previous axillary lymph node dissection

          -  Neoadjuvant chemotherapy or hormonal therapy exceeding greater than 30 days duration

          -  Allergy to blue dyes or iodine; NOTE: a non-blue dye or non-iodine-containing dye may
             be used in these patients

          -  Patients with implanted medical devices such as a pacemaker may undergo perometry, but
             not BIS (Bioelectrical Impedance Spectroscopy)

          -  Previous diagnosis of LE (lymphedema) of either extremity

          -  Bilateral axillary staging
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Holmes</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <results_first_submitted>July 1, 2014</results_first_submitted>
  <results_first_submitted_qc>July 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2014</results_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for this trial opened in December 2010 and closed in June 2011 at which time the protocol was terminated due to the departure of the Principal Investigator.</recruitment_details>
      <pre_assignment_details>The study has no pre-assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SNB Plus ARM or ALND (+/- SNB) Plus ARM</title>
          <description>Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
technetium Tc 99m sulfur colloid: Given intradermally and periareolarly
methylene blue: Given subcutaneously
indocyanine green solution: Given subcutaneously
sentinel lymph node biopsy: Undergo sentinel lymph node biopsy
axillary lymph node biopsy: Undergo axillary lymph node biopsy
bioimpedance spectroscopy: Correlative studies
quality-of-life assessment: Ancillary studies
lymphedema management: Undergo axillary reverse mapping</description>
        </group>
        <group group_id="P2">
          <title>SNB or ALND (+/- SNB)</title>
          <description>Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
technetium Tc 99m sulfur colloid: Given intradermally and periareolarly
methylene blue: Given subcutaneously
indocyanine green solution: Given subcutaneously
sentinel lymph node biopsy: Undergo sentinel lymph node biopsy
axillary lymph node biopsy: Undergo axillary lymph node biopsy
bioimpedance spectroscopy: Correlative studies
quality-of-life assessment: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No one to oversee trial after P.I. left</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SNB Plus ARM or ALND (+/- SNB) Plus ARM</title>
          <description>Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
technetium Tc 99m sulfur colloid: Given intradermally and periareolarly
methylene blue: Given subcutaneously
indocyanine green solution: Given subcutaneously
sentinel lymph node biopsy: Undergo sentinel lymph node biopsy
axillary lymph node biopsy: Undergo axillary lymph node biopsy
bioimpedance spectroscopy: Correlative studies
quality-of-life assessment: Ancillary studies
lymphedema management: Undergo axillary reverse mapping</description>
        </group>
        <group group_id="B2">
          <title>SNB or ALND (+/- SNB)</title>
          <description>Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
technetium Tc 99m sulfur colloid: Given intradermally and periareolarly
methylene blue: Given subcutaneously
indocyanine green solution: Given subcutaneously
sentinel lymph node biopsy: Undergo sentinel lymph node biopsy
axillary lymph node biopsy: Undergo axillary lymph node biopsy
bioimpedance spectroscopy: Correlative studies
quality-of-life assessment: Ancillary studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Whether or Not a Patient Has Developed Grade 1+ LE</title>
        <description>LE is defined using the CTCAE v3 definition: a &gt;5-10% increase in the inter-limb volume in the ipsilateral arm compared to the unaffected arm.</description>
        <time_frame>During the first year post-operatively</time_frame>
        <population>Unable to analyze due to early termination of the study</population>
        <group_list>
          <group group_id="O1">
            <title>SNB Plus ARM or ALND (+/- SNB) Plus ARM</title>
            <description>Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
technetium Tc 99m sulfur colloid: Given intradermally and periareolarly
methylene blue: Given subcutaneously
indocyanine green solution: Given subcutaneously
sentinel lymph node biopsy: Undergo sentinel lymph node biopsy
axillary lymph node biopsy: Undergo axillary lymph node biopsy
bioimpedance spectroscopy: Correlative studies
quality-of-life assessment: Ancillary studies
lymphedema management: Undergo axillary reverse mapping</description>
          </group>
          <group group_id="O2">
            <title>SNB or ALND (+/- SNB)</title>
            <description>Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
technetium Tc 99m sulfur colloid: Given intradermally and periareolarly
methylene blue: Given subcutaneously
indocyanine green solution: Given subcutaneously
sentinel lymph node biopsy: Undergo sentinel lymph node biopsy
axillary lymph node biopsy: Undergo axillary lymph node biopsy
bioimpedance spectroscopy: Correlative studies
quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Whether or Not a Patient Has Developed Grade 1+ LE</title>
          <description>LE is defined using the CTCAE v3 definition: a &gt;5-10% increase in the inter-limb volume in the ipsilateral arm compared to the unaffected arm.</description>
          <population>Unable to analyze due to early termination of the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months from date on study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SNB Plus ARM or ALND (+/- SNB) Plus ARM</title>
          <description>Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
technetium Tc 99m sulfur colloid: Given intradermally and periareolarly
methylene blue: Given subcutaneously
indocyanine green solution: Given subcutaneously
sentinel lymph node biopsy: Undergo sentinel lymph node biopsy
axillary lymph node biopsy: Undergo axillary lymph node biopsy
bioimpedance spectroscopy: Correlative studies
quality-of-life assessment: Ancillary studies
lymphedema management: Undergo axillary reverse mapping</description>
        </group>
        <group group_id="E2">
          <title>SNB or ALND (+/- SNB)</title>
          <description>Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
technetium Tc 99m sulfur colloid: Given intradermally and periareolarly
methylene blue: Given subcutaneously
indocyanine green solution: Given subcutaneously
sentinel lymph node biopsy: Undergo sentinel lymph node biopsy
axillary lymph node biopsy: Undergo axillary lymph node biopsy
bioimpedance spectroscopy: Correlative studies
quality-of-life assessment: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema - limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Mastectomy site</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early due to P.I. moving to another institution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Victoria Soto, Project Specialist, Clinical Investigations Support Office</name_or_title>
      <organization>USC Norris Comprehensive Cancer Center</organization>
      <phone>323-226-6384</phone>
      <email>victoria.soto@med.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

